Foghorn Therapeutics Inc. (FHTX) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
FHTX Revenue Growth
FHTX Revenue Analysis (2018–2025)
As of May 9, 2026, Foghorn Therapeutics Inc. (FHTX) generated trailing twelve-month (TTM) revenue of $30.9 million, reflecting explosive growth of +223.8% year-over-year. The most recent quarter (Q4 2025) recorded $9.2 million in revenue, up 13.4% sequentially.
Looking at the longer-term picture, FHTX's 5-year compound annual growth rate (CAGR) stands at +135.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $34.2 million in 2023.
When compared to Healthcare sector peers including TNGX (+48.3% YoY), VYNE (+13.8% YoY), and AUPH (+20.4% YoY), FHTX has outperformed the peer group in terms of revenue growth. Compare FHTX vs TNGX →
FHTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FHTXCurrent | $31M | +223.8% | +135.1% | -265.6% | |
 TNGX | $62M | +48.3% | +52.1% | -178.4% | |
 VYNE | $570,000 | +13.8% | -51.4% | -5219.1% | |
 AUPH | $283M | +20.4% | +41.4% | 37.1% |
FHTX Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $30.9M | +36.8% | $27.6M | 89.2% | $-82,107,000 | -265.6% |
| 2024 | $22.6M | -33.8% | $22.6M | 100.0% | $-102,683,000 | -454.3% |
| 2023 | $34.2M | +77.6% | $34.2M | 100.0% | $-107,906,000 | -315.9% |
| 2022 | $19.2M | +1357.8% | $19.2M | 100.0% | $-117,137,000 | -609.2% |
| 2021 | $1.3M | +206.7% | $1.3M | 100.0% | $-100,734,000 | -7637.1% |
| 2020 | $430K | - | $-57,285,000 | -13322.1% | $-68,531,000 | -15937.4% |
| 2019 | $0 | - | $-1,793,000 | - | $-51,084,000 | - |
| 2018 | $0 | - | $-379,000 | - | $-26,049,000 | - |
See FHTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FHTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FHTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFHTX — Frequently Asked Questions
Quick answers to the most common questions about buying FHTX stock.
Is FHTX's revenue growth accelerating or slowing?
FHTX revenue is accelerating at +223.8% year-over-year, exceeding the 5-year CAGR of +135.1%. TTM revenue reached $31M. Growth momentum has increased versus prior periods.
What is FHTX's long-term revenue growth rate?
Foghorn Therapeutics Inc.'s 5-year revenue CAGR of +135.1% reflects the sustained expansion pattern. Current YoY growth of +223.8% is above this long-term average.
How is FHTX's revenue distributed by segment?
FHTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.